Crystal Pharmatech Co., Ltd.

Xiaojuan Diao

Yanfeng Zhang

Minhua Chen

Xiaoyu Zhang

Nan Xia

The present disclosure relates to a novel crystalline form of lenvatinib mesylate and the preparation method thereof. The novel crystalline form of mesylate of the present disclosure can be used for treating invasive and differentiated thyroid cancer. The novel crystalline form of mesylate of the present disclosure has good solubility, stability, and remarkable purification effect in process. The preparation method of this novel crystalline form is simple, low cost, and has an important value for future optimization and development of the drug. 

Crystalline form of lenvantinib mesylate and process of preparation thereof

The present disclosure relates to novel crystalline forms of JAK inhibitors and the preparation method thereof. The novel crystalline forms in the present disclosure can be used for the treatment of autoimmune diseases, particularly for the treatment of rheumatoid arthritis. The novel crystalline forms in the present disclosure have good stability and remarkable purification effect in process, moreover, its solubility and hygroscopicity meet the requirements for medical use. The preparation method of novel crystalline forms is simple, low cost, and has an important value for future optimization and development of the drug. 

Crystal form of JAK inhibitor and preparation method thereof

The present invention relates to crystalline Form A of obeticholic acid and the preparation method thereof. The present invention provides Form A having characteristic peaks at 2theta value of 4.9&#xb0;&#xb1;0.2&#xb0;, 5.2&#xb0;&#xb1;0.2&#xb0;, 9.9&#xb0;&#xb1;0.2&#xb0;. The present invention provides a novel crystalline form of obeticholic acid, which has good stability, good processability and other favorable properties, and is suitable for storage and usage as a final product. In addition, the preparation method is simple, low cost, and has great value for the future optimization and development of obeticholic acid.

Crystalline form A of obeticholic acid and preparation method thereof

Crystal form of lenvatinib methanesulfonate salt and preparation method thereof

The present invention relates to novel crystalline forms of Neratinib maleate and the preparation method thereof. The novel crystalline forms of Neratinib maleate in the present invention have high solubility, good stability, good processability, easy post-treatment process and other favorable properties. The preparation method is simple, low cost, and has an important value for future optimization and development of the drug.

Crystal form of neratinib maleate and preparation method therefor

The present disclosure relates to crystalline Form &#x3b1; of a compound of formula (I) used for preparing a blood-cancer drug and preparation method thereof. The crystalline Form &#x3b1; in the present disclosure has better stability, and its solubility and hygroscopicity meet the requirements of medical use. Form &#x3b1; has simple preparation method and low manufacturing cost, and provides great value to future optimization and development of this drug. 

Growing community of inventors

Jiangsu, China

Xiaojuan Diao